Dermabacter hominis

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Dermabacter hominis is a Gram-positive, non-spore-forming, facultatively anaerobic, non-motile, rod-shaped bacterium. It has been detected in at least 6 gut microbiome compilation studies or metastudies. The DNA G+C content is 62%. Dermabacter hominis is probably a rare gut coloniser. (Jones1988)



  • This organism has been recovered from human skin, clinical sources (blood, wound, abscess - CCUG; fatal septicaemia) and human faeces. The risk classification (www.baua.de) for this organism is 1, i.e., low risk of infection and spread (notes: opportunistic in immunocompromised patients). It is an opportunistic pathogen. Is a known gut commensal.
    • GENERAL CHARACTERISTICS (Jones1988);
    Character Response
  • Substrates hydrolysed or digested:
  • aesculin; casein; gelatin; starch;
  • 🧂
  • Salt tolerance:
  • tolerates 5% salt;
  • 🌡
  • Temperature tolerance:
  • doesn't grow at 10℃; grows at 37℃; strain-variable at 45(d);
  • H+
  • Acid from carbohydrates usually produced:
  • fructose; galactose; glucose; mannose; ribose; amygdalin; cellubiose; gentiobiose; lactose; maltose; melezitose; melibiose; raffinose; sucrose; trehalose; D-turanose; N-Ac glucosamine;
  • ±
  • Strain-dependent acid from carbs:
  • D-lyxose;
  • Active enzymes:
  • N-Ac β-glucosaminidase; catalase; esterase lipase C8; β-galactosidase; α-glucosidase; lecithinase; Leu arylamidase; α-mannosidase; pyrrolidine arylamidase;
    • SPECIAL FEATURES (Jones1988);
    Character Response
  • ✓
  • Metabolites produced:
  • H₂S (variable);
  • ✗
  • Metabolites not produced:
  • indole;
  • ✗
  • VP test:
  • not active
  • ✗
  • Nitrate:
  • not reduced
    • RESPONSE TO ANTIBIOTICS (Troxler2001);
    Class Active Resistant
  • Penicillins:
  • amoxicillin; ampicillin-sulbactam; azlocillin; imipenem; meropenem; mezlocillin; penicillin; piperacillin; ticarcillin;
  • Cephalosporins:
  • cefaclor; cefazolin; cefdinir; cefepime; cefotaxime; cefotiam; cefoxitin; cefpodoxime; cefuroxime;
  • Macrolides:
  • clarithromycin; quinupristin-dalfopristin;
  • Tetracyclines:
  • doxycycline; minocycline;
  • Quinolines:
  • enoxacin; pipemidic-acid;
  • Aminoglycosides:
  • amikacin; spectinomycin;
  • apramycin; tobramycin;
  • Heterocycles:
  • fusidic-acid;
  • co-trimoxazole; sulfamethoxazole; trimethoprim;
  • Vancomycins:
  • vancomycin; teicoplanin;
  • Miscellaneous antibiotics:
  • linezolid;

  • Lagier, J.-C., Armougom, F., Million, M., Hugon, P., Pagnier, I., Robert, C., Bittar, F., Fournous, G., Gimenez, G., Maraninchi, M., Trape, J.-F., Koonin, E. V., La Scola, B., & Raoult, D. (2012). Microbial culturomics: paradigm shift in the human gut microbiome study. Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 18(12), 1185–1193.

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Actinobacteria Class:  Actinomycetia Order:  Micrococcales Family:  Dermabacteraceae Genus:  Dermabacter Gram stain:  + O2 Relation.:  facultatively anaerobic Spore:  No spore Motility:  Sessile Morphology:  Rod
    Health:  Unknown
    Source:  human skin, clinical sources (blood, wound, abscess - CCUG; fatal septicaemia) and human faeces
    DNA G+C(%):  62
    Low T(℃):  10(neg)
    Mid T(℃):  37(+)
    High T(℃):  45(d)
    NaCl 3-5%:  5(+)
    		Aesculin:  + Urea:  neg Gelatin:  + Starch:  + Casein:  + Arginine:  neg Tyrosine:  neg Hippurate:  neg Tween:  80(d(w))
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    Arabinose:  neg L-Arabinose:  neg Fructose:  + Fucose:  neg D-Fucose:  neg Galactose:  + Glucose:  + Mannose:  + D-Lyxose:  d Rhamnose:  neg Ribose:  + D-Tagatose:  neg Xylose:  vr L-Xylose:  neg Cellubiose:  + Gentiobiose:  + Lactose:  + Maltose:  + Melezitose:  + Melibiose:  + Sucrose:  + Trehalose:  + Turanose:  + Amygdalin:  + Dextrin:  neg Glycogen:  neg Inulin:  neg Adonitol:  neg D-Arabitol:  neg L-Arabitol:  neg Dulcitol:  neg Erythritol:  neg Glycerol:  neg Inositol:  neg Mannitol:  neg Sorbitol:  neg Xylitol:  neg Arbutin:  vr Gluconate:  neg 2-Ketogluconate:  neg 5-Ketogluconate:  neg Me-α-D-Glc:  vr Me-α-D-Mann:  neg Me-Xyloside:  neg NAc-α-GA:  + Salicin:  vr
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Oxidase:  neg Catalase:  + Urease:  neg Ac-β-glcamnd:  + α-Fucosidase:  neg α-Galactosidase:  neg β-Galactosidase:  + α-Glucosidase:  + β-Glucosidase:  neg β-Glucuronidase:  neg α-Mannosidase:  + β-Mannosidase:  neg ArgDH:  neg γ-Glu transf.:  neg LysDC:  neg OrnDC:  neg AlaPheProAA:  neg LeuAA:  + PyrrolidAA:  + ValAA:  neg AcidP:  vr Esterase(C4):  vr EstLip(C8):  + Lecithinase:  + Lipase:  neg Lipase(C14):  neg
    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    		H2S:  vr Indole:  neg
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    amoxicillin:  SensRNG: (0.06-4)
    amp-sulb:  SensRNG: (0.06-2)
    azlocillin:  S(0.25)
    aztreonam:  Var(MIC50): 0.5-128), MIC90: Var(0.5-128
    benzyl-pen:  Var
    mezlocillin:  SensRNG: (0.13-0.5)
    oxacillin:  Var(MIC50): 0.01-16), MIC90: Var(0.01-16
    penicillin:  S(MIC50): 0.125, MIC90: 1, RNG: (0.02-4)
    piperacillin:  SensRNG: (0.13-1)
    piper-taz:  Var(MIC50): 0.25, MIC90: 16, RNG: (0.02-16)
    ticarcillin:  SensRNG: (0.13-2)
    imipenem:  S(MIC50): 0.03, MIC90: 0.25, RNG: (≤0.015-4)
    meropenem:  SensRNG: (0.03-0.5)
    cefaclor:  SensRNG: (0.06-32)
    cefazolin:  SensRNG: (0.13-2)
    cefdinir:  SensRNG: (0.03-2)
    cefepime:  SensRNG: (0.03-2)
    cefixime:  Var(MIC50): 0.03-32), MIC90: Var(0.03-32
    cefotaxime:  SensRNG: (0.03-4)
    cefotiam:  SensRNG: (0.03-4)
    cefoxitin:  SensRNG: (0.03-2)
    cefpodoxime:  SensRNG: (0.01-1)
    cefuroxime:  SensRNG: (0.03-8)
    amikacin:  SensRNG: (4-16)
    apramycin:  Res
    gentamicin:  Var(MIC50): 1-16), MIC90: Var(1-16
    kanamycin:  Var(MIC50): 1-256), MIC90: Var(1-256
    neomycin:  Var(MIC50): 1-256), MIC90: Var(1-256
    spectinomycin:  SensRNG: (1-8)
    streptomycin:  Var(MIC50): 1-64), MIC90: Var(1-64
    tobramycin:  R(8-256)
    erythromycin:  Var(MIC50): 0.06, MIC90: ≥64, RNG: (≤0.06-64)
    clarithromycin:  SensRNG: (0.03-8)
    quin-dalf:  S(MIC50): 0.25, MIC90: 1, RNG: (0.06-2)
    roxithromycin:  Var(MIC50): 0.03-128), MIC90: Var(0.03-128
    linezolid:  S(MIC50): 0.5, MIC90: 1, RNG: (0.125-1)
    ciprofloxacin:  Var(MIC50): 0.13-1), MIC90: Var(0.13-1
    enoxacin:  Res
    norfloxacin:  Var(MIC50): 1-32), MIC90: Var(1-32
    pipemidic_acid:  Res
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    doxycycline:  SensRNG: (0.25-2)
    minocycline:  SensRNG: (0.25-2)
    tetracycline:  Var(MIC50): 2-32), MIC90: Var(2-32
    teicoplanin:  SensRNG: (0.06-0.25)
    vancomycin:  S(MIC50): 0.5, MIC90: 1, RNG: (0.25-4)
    rifampicin:  Var(MIC50): 0.01-32), MIC90: Var(0.01-32
    chloramphenicol:  Var(MIC50): 0.25-64), MIC90: Var(0.25-64
    fosfomycin:  Var(MIC50): 8-256), MIC90: Var(8-256
    nitrofurantoin:  Var(MIC50): 16-128), MIC90: Var(16-128
    sulfamethoxazole:  Res
    trimethoprim:  Res
    co-trimoxazole:  Res
    clindamycin:  Var(MIC50): 0.03-64), MIC90: Var(0.03-64
    lincomycin:  Var(MIC50): 0.06-64), MIC90: Var(0.06-64
    daptomycin:  Var(MIC50): 0.125, MIC90: 8, RNG: (0.02-8)
    fusidic-acid:  SensRNG: (0.13-1)

    References

    SPECIFIC REFERENCES FOR DERMABACTER HOMINIS
  • Jones1988 - Taxonomic studies on some human cutaneous coryneform bacteria: Description of Dermabacter hominis gen. nov., sp. nov.
  • Troxler2001 - Natural Antibiotic Susceptibility of Recently Established Coryneform Bacteria.
  • Cassir2015 - Clostridium butyricum Strains and Dysbiosis Linked to Necrotizing Enterocolitis in Preterm Neonates
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR DERMABACTER HOMINIS
  • Cassir2015 - Clostridium butyricum Strains and Dysbiosis Linked to Necrotizing Enterocolitis in Preterm Neonates
  • Dubourg2013 - The gut microbiota of a patient with resistant tuberculosis is more comprehensively studied by culturomics than by metagenomics.
  • Forster2019 - A human gut bacterial genome and culture collection for improved metagenomic analyses.
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • Pfleiderer2013 - Culturomics identified 11 new bacterial species from a single anorexia nervosa stool sample.
  • RajilicStojanovic2014 - The first 1000 cultured species of the human gastrointestinal microbiota.
  • ...............................
    • Added: April 08, 2021